SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
MariMed Inc. (MRMD) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+3025%).
- 分析师共识目标价 $2.25 (+3025% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 46/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
17/100
Debt-to-Equity & liquidity
→ Health
估值概览 — MRMD
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.18
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.04
每股账面价值$0.00
每股营收$0.41
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$2.25 (+3025%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$0.00 |
$3.56M |
$-198.85K |
-5.6% |
| 2017 |
$-0.01 |
$6.07M |
$-1.19M |
-19.7% |
| 2018 |
$-0.07 |
$11.85M |
$-13.6M |
-114.8% |
| 2019 |
$-0.32 |
$45.6M |
$-66.52M |
-145.9% |
| 2020 |
$0.01 |
$50.9M |
$2.14M |
4.2% |
| 2021 |
$0.02 |
$121.46M |
$7.23M |
5.9% |
| 2022 |
$0.04 |
$134.01M |
$13.47M |
10% |
| 2023 |
$-0.04 |
$148.6M |
$-16.03M |
-10.8% |
| 2024 |
$-0.03 |
$157.96M |
$-12.16M |
-7.7% |
| 2025 |
$-0.04 |
$159.83M |
$-14.48M |
-9.1% |
